Pfizer Completes Acquisition of Baxter’s Vaccine Portfolio
Pfizer has completed the acquisition of Baxter International’s portfolio of marketed vaccines. The vaccines acquired consists of NeisVac-C and FSME-IMMUN/TicoVac. As previously announced, Pfizer also acquired a portion of Baxter's facility in Orth, Austria, where these vaccines are manufactured.
NeisVac-C is a vaccine that helps protect against meningitis caused by group C meningococci(MenC). FSME-IMMUN/TicoVac is a vaccine that helps protect against tick-borne encephalitis (TBE), an infection of the brain, which is transmitted by the bite of ticks infected with the TBE-virus.